Schächinger et al. 1 recently reported clinical improvement after treatment of acute myocardial infarction with intracoronary injection of autologous bone-marrowderived mononuclear cells (MNCs) (the REPAIR-AMI Trial). Here, the authors discuss whether lack of improvement in global left ventricular function in our study, the ASTAMI study, 2 could be related to impaired cell quality or insufficient cell numbers. We believe this is unlikely for the following reasons: However, we believe that factors other than administration of BMCs may have influenced left ventricular ejection fraction (LVEF) recovery and, hence, clinical outcomes in their study. First, we can suppose that spontaneous LVEF recovery was already occurring in both groups before BMCs or placebo administration. Indeed, baseline LVEF was 46.7 + 10 and 47.5 + 10% in controls and BMC-treated patients, respectively-values higher than that used as a threshold for patient inclusion in the study ( 45%). This spontaneous recovery may be explained by the mean delay between enrolment and baseline LVEF measurement (4.3 + 1.3 days). Secondly, and more importantly, two major determinants of LVEF recovery-time-to-reperfusion and infarct location-are possible confounders in this study. According to Sheiban et al., 3 LVEF recovery is usually observed after primary angioplasty if coronary flow is restored 4 h from symptom onset, whereas no significant improvement occurs afterwards. This time "window" may be even narrower in anterior infarctions. Indeed, we have observed no significant recovery in LVEF after primary angioplasty despite an average shorter time-toreperfusion (2.5 + 1.4 h) when only anterior myocardial infarctions were considered. 4 In the REPAIR-AMI study, however, the authors analysed anterior and inferior infarctions together, despite the fact that these two infarct locations differ in terms of acute left ventricular impairment severity, LVEF recovery and clinical outcome after reperfusion therapy. 5, 6 In BMC-treated patients, anterior infarctions were less represented (64 vs. 76%), which may explain the small difference in LVEF recovery between the placebo and treated groups (3.0 + 6.5 vs. 5.5 + 7.3%), and in clinical outcomes. 1, 2 Moreover, mean reperfusion time was !7 h, an interval usually not associated with LVEF improvement, particularly in anterior infarctions. 
